Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.64 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.64 |
| ▸ | HRH1 | P35367 | 4/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.60 |
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7902062 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL5987924 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL7773873 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL783035 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL8499157 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL7865088 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL23070514 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL133039 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL8499165 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL130279 | 1.00 | MAOA (0.95) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 552 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875115-A1 | ANTI-CGRP COMPOSITIONS AND USE THEREOF | H. Lundbeck A/S (DK) | 2021-09-08 | — | — | EP | claimed |
| CN-108424452-B | anti-CGRP compositions and uses thereof | H.伦德贝克公司 | 2021-08-03 | — | — | CN | claimed |
| US-20210047391-A1 | ANTI-CGRP COMPOSITIONS AND USE THEREOF | ALDERBIO HOLDINGS LLC | 2021-02-18 | — | — | US | claimed |
| EP-2710039-B1 | ANTI-CGRP COMPOSITIONS AND USE THEREOF | ALDERBIO HOLDINGS LLC (US) | 2019-01-09 | — | — | EP | claimed |
| EP-2710039-A2 | ANTI-CGRP COMPOSITIONS AND USE THEREOF | AlderBio Holdings LLC (US) | 2014-03-26 | — | — | EP | claimed |
| WO-2012162243-A2 | ANTI-CGRP COMPOSITIONS AND USE THEREOF | ALDERBIO HOLDINGS LLC (US) | 2012-11-29 | — | — | WO | claimed |
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2003-05-01 | — | — | US | claimed |
| JP-2002516305-A | — | — | 2002-06-04 | — | — | JP | claimed |
| EP-1132370-A2 | Process for producing n-substituted polyhydroxy nitrogen-containing heterocyles | MONSANTO COMPANY (US) | 2001-09-12 | — | — | EP | claimed |
| US-20010019837-A1 | PROCESS FOR MICROBIALLY OXIDIZING N-SUBSTITUTED GLUCAMINES | GRABNER ROY WALTER (US) | 2001-09-06 | — | — | US | claimed |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | WYETH | 2001-08-30 | — | — | US | claimed |
| EP-1077929-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061410-A1 | 2,3,5-SUBSTITUTED BIPHENYLS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | claimed |
| EP-0770387-B1 | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic | BRAUN MELSUNGEN AG (DE) | 1999-08-11 | — | — | EP | claimed |
| EP-0770387-A1 | Pharmaceutical composition containing a local anesthetic and/or centrally acting analgesic | B. BRAUN MELSUNGEN AG (DE) | 1997-05-02 | — | — | EP | claimed |
| EP-0624652-A1 | Process for producing N-substituted polyhydroxy nitrogen-containing heterocycles | MONSANTO COMPANY (US) | 1994-11-17 | — | — | EP | claimed |
| EP-0477160-A1 | Process for producing N-substituted-1-deoxynojirimycin | MONSANTO COMPANY (US) | 1992-03-25 | — | — | EP | claimed |
| CN-119303074-A | Treatment of drug abuse headache with anti-CGRP or anti-CGRP-R antibodies | H.隆德贝克有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-0002721-B1 | PROCESS FOR PREPARING HYDRAZINES | BAYER AG (DE) | 1981-09-02 | — | — | EP | disclosed |
| EP-0002721-A2 | Process for preparing hydrazines | BAYER AG (DE) | 1979-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083341-A1 | 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | MAOA 3814/4885HTR2A 1384/4885CYP2A6 224/4885 |
| US-20010018525-A1 | 2, 3, 5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia | INSR, GPR119, IRS1 | MAOA 3817/4885HTR2A 1387/4885CYP2A6 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.